Will CVS's earnings momentum continue post-Q4 2024?

**CVS's earnings momentum is likely to continue post-Q4 2024**, based on several key factors:

1. **Positive Outlook for 2025**: CVS has projected higher earnings for 2025 compared to 2024, with adjusted EPS expected to rebound with a 10.7% year-over-year growth. This indicates a potential upswing in earnings momentum.
2. **Strong Performance in Key Segments**: The pharmacy and consumer wellness segments have shown growth, which is a positive indicator for future earnings. These segments are likely to contribute positively to CVS's earnings momentum.
3. **Improving Revenue Projections**: CVS anticipates revenue growth for 2025, with a forecasted minimum of $385.9 billion, compared to $372.81 billion in 2024. This suggests a favorable outlook for revenue, which is a key driver of earnings.
4. **Medical Benefits Ratio Improvement**: The company expects its medical benefits ratio to improve by 100 basis points over 2024, which could lead to better profitability and earnings momentum. An improved medical benefits ratio typically indicates more efficient cost management.
5. **Investor Confidence**: Despite recent challenges, analysts' consensus views on CVS Health stock is cautiously optimistic, with a "Moderate Buy" rating. This sentiment could translate into continued earnings momentum as investors remain positive about CVS's long-term prospects.

In conclusion, while CVS has faced some challenges, particularly in its Health Care Benefits segment, the company's strategic positioning, projected revenue growth, and anticipated improvements in key financial metrics suggest that its earnings momentum could continue post-Q4 2024.